European Commission (1996) *Technical guidance document in support of Commission Directive 93/67/EEC on risk assessment for new notified substances and Commission Regulation (EC) No 1488/94 on risk assessment for existing substances*
This specific and rapid tumor accumulation, the lack of competition with daratumumab and rapid clearance make sdAb#2F8 an ideal candidate for an imaging approach to also assess response during daratumumab treatment [108]
This Protein Provide 7 Gram (BCAA) Per Serving To stimulate Human Muscle Protein synthesis primarily by activating the mTOR signalling Anabolic pathway
Open Heart (2019) 6:e000993
In contrast, in developed countries, accidental or occupational exposures predominate, often due to industrial spills or contaminated food sources
Supplementary information Supplementary Table 1 (download XLSX Antibodies for immunoblotting Supplementary Table 2 (download XLSX Primers for qPCR Supplementary Table 3 (download XLSX List of quantified proteins with abundance ratio from LX-2 cells Supplementary Table 4 (download XLSX Quantification for -SMA and APOL2 immunostaining in human liver tissues Supplementary Table 5 (download XLSX List of proteins that interact with APOL2 in LX-2 cells Supplementary Table 6 (download XLSX RNA-seq data in LX-2 cells treated with DP Supplementary Table 7 (download XLSX Statistical source data for immunoblot quantitation Raw figures for IHC or H&E photos Source data Unprocessed western blots
